Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Hadasit Surges Most in 4 Months After Unit Gets FDA Approval

Feb. 28 (Bloomberg) -- Hadasit Bio-Holdings Ltd. surged the most in more than four months after a unit got investigational new drug approval from the U.S. Food and Drug Administration for a Phase II clinical trial for blood clotting.

Shares of the developer of diagnostic and treatment products rallied 9.6 percent, the most since Oct. 25, to 0.559 shekel at the 4:30 p.m. close in Tel Aviv.

To contact the reporter on this story: Shoshanna Solomon in Tel Aviv at

To contact the editor responsible for this story: Claudia Maedler at

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.